Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:15am, Wednesday, 06'th May 2026
Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
08:00am, Wednesday, 06'th May 2026
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Na
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
12:54am, Wednesday, 06'th May 2026
Halozyme (HALO) is evolving from an ENHANZE royalty story into a diversified subcutaneous drug delivery platform, expanding its technology suite and partner base. FY 2025 royalty revenue surged 52% to
Halozyme to Report First Quarter 2026 Financial and Operating Results
04:30pm, Thursday, 30'th Apr 2026
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 30'th Apr 2026
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
08:00am, Thursday, 30'th Apr 2026
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, eff
Active Management Shines Bright With This Commodities ETF
01:46pm, Wednesday, 29'th Apr 2026
Due in large part to soaring energy prices, investors holding basic energy sector ETFs are being rewarded this year. However, oil isn't the only commodity setting a torrid pace.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release
11:08am, Tuesday, 28'th Apr 2026
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
09:35am, Wednesday, 22'nd Apr 2026
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designe
Goldman's HALO Trade Could Be the 2026 Edge Investors Are Missing
10:11am, Friday, 10'th Apr 2026
Goldman Sachs (NYSE:GS) has a pretty interesting strategy for investors who aren't yet comfortable braving the dip in some of the hardest-hit stocks, specifically in tech.
Helen Torley Sells 10,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock
04:02am, Thursday, 09'th Apr 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the business's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages
02:15am, Wednesday, 08'th Apr 2026
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) have earned an average recommendation of "Hold" from the twelve analysts that are currently covering the company, Marketbeat Rati
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
08:00am, Tuesday, 07'th Apr 2026
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a g
SG Americas Securities LLC Purchases 9,260 Shares of Halozyme Therapeutics, Inc. $HALO
04:47am, Sunday, 05'th Apr 2026
SG Americas Securities LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 35.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange C
Element Squared LLC Invests $1.19 Million in Halozyme Therapeutics, Inc. $HALO
05:04am, Saturday, 04'th Apr 2026
Element Squared LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the fourth quarter, according to the company in its most recent disclosure with the Securities
